US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience

Documenti analoghi

• Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
  di: Gabriel K. Innes, et al.
  Pubblicazione: (2025)
• Evidence Generation for Drugs and Biological Products isn't Magic or Myth
  di: John Concato, et al.
  Pubblicazione: (2025)
• The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
  di: Rajanikanth Madabushi, et al.
  Pubblicazione: (2024)
• Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021
  di: Yoona Choi, et al.
  Pubblicazione: (2025)
• Trust in the Food and Drug Administration: A National Survey Study
  di: William B. Feldman, et al.
  Pubblicazione: (2024)